1-17 of 17
Jun Guo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

Lili Mao, Meiyu Fang, Yu Chen, Xiaoting Wei, Jun Cao, Jing Lin, Peng Zhang, Ling Chen, Xiao Cao, Yujun Chen, Jun Guo, Lu Si
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4642–4648.
https://doi.org/10.1158/1078-0432.CCR-22-1528
Published: 01 November 2022
View article titled, Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Open the PDF for Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study in another window
Includes: Supplementary data
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng, Haige Chen, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyan Liu, Jin Wu, FangJian Zhou, Zhisong He, Jinhai Fan, Weifeng Wang, Hui Feng, Sheng Yao, Patricia Keegan, Yiran Huang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 489–497.
https://doi.org/10.1158/1078-0432.CCR-21-2210
Published: 01 February 2022
View article titled, Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 in another window
Includes: Supplementary data
Journal Articles

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

Xue Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit Pallan, Catriona Harvey, Michael P. Manos, Olivia Ouyang, Michelle S. Kim, Gyulnara Kasumova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Tatyana Sharova, Dennie T. Frederick, Keith T. Flaherty, Osama E. Rahma, Georgina V. Long, Alexander M. Menzies, Jun Guo, Alexander N. Shoushtari, Douglas B. Johnson, Ryan J. Sullivan, Genevieve M. Boland
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5993–6000.
https://doi.org/10.1158/1078-0432.CCR-21-1283
Published: 01 November 2021
View article titled, Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
Open the PDF for Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy in another window
Includes: Supplementary data
Journal Articles

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Changlu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-20-2488
Published: 04 January 2021
View article titled, Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Open the PDF for Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 5048.
https://doi.org/10.1158/1078-0432.CCR-20-3168
Published: 15 September 2020
View article titled, Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Open the PDF for Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial in another window
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

Bixia Tang, Zhihong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4250–4259.
https://doi.org/10.1158/1078-0432.CCR-19-3922
Published: 14 August 2020
View article titled, Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial in another window
Includes: Supplementary data
Journal Articles

Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu, Xue Bai, Jian Wang, Xin-Ran Tang, De-Hua Wu, Sha-Sha Du, Xiu-Ju Du, Yao-Wei Zhang, Hong-Bo Zhu, Yuan Fang, Ze-Qin Guo, Qin Zeng, Xue-Jun Guo, Zhu Liu, Zhong-Yi Dong
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7413–7423.
https://doi.org/10.1158/1078-0432.CCR-19-0558
Published: 13 December 2019
View article titled, Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Open the PDF for Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Jiayi Yu, Junya Yan, Qian Guo, Zhihong Chi, Bixia Tang, Bin Zheng, Jinyu Yu, Ting Yin, Zhiyuan Cheng, Xiaowen Wu, Huan Yu, Jie Dai, Xinan Sheng, Lu Si, Chuanliang Cui, Xue Bai, Lili Mao, Bin Lian, Xuan Wang, Xieqia Yan, Siming Li, Li Zhou, Keith T. Flaherty, Jun Guo, Yan Kong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (21): 6511–6523.
https://doi.org/10.1158/1078-0432.CCR-19-0475
Published: 01 November 2019
View article titled, Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Open the PDF for Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma in another window
Includes: Supplementary data
Journal Articles

L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma

Jiu-Yang Zhang, Pei-Pei Zhang, Wen-Ping Zhou, Jia-Yu Yu, Zhi-Hua Yao, Jun-Feng Chu, Shu-Na Yao, Cheng Wang, Waseem Lone, Qing-Xin Xia, Jie Ma, Shu-Jun Yang, Kang-Dong Liu, Zi-Gang Dong, Yong-Jun Guo, Lynette M. Smith, Timothy W. McKeithan, Wing C. Chan, Javeed Iqbal, Yan-Yan Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 4168–4178.
https://doi.org/10.1158/1078-0432.CCR-18-2146
Published: 01 July 2019
View article titled, L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Open the PDF for L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong, Xinan Sheng, Xiaowen Wu, Junya Yan, Meng Ma, Jiayi Yu, Lu Si, Zhihong Chi, Chuanliang Cui, Jie Dai, Yiqian Li, Huan Yu, Tianxiao Xu, Huan Tang, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (22): 6946–6957.
https://doi.org/10.1158/1078-0432.CCR-17-0070
Published: 14 November 2017
View article titled, Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Open the PDF for Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Xue Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian, Xieqiao Yan, Li Zhou, Jie Dai, Jun Guo, Lu Si
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6120–6127.
https://doi.org/10.1158/1078-0432.CCR-17-0980
Published: 12 October 2017
View article titled, <em>MAPK</em> Pathway and <em>TERT</em> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases
Open the PDF for <em>MAPK</em> Pathway and <em>TERT</em> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases in another window
Includes: Supplementary data
Journal Articles

Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells

Wei Zhang, Bin Yi, Chao Wang, Dongquan Chen, Sejong Bae, Shi Wei, Rong-Jun Guo, Changming Lu, Lisa L.H. Nguyen, Wei-Hsiung Yang, James W. Lillard, Xingyi Zhang, Lizhong Wang, Runhua Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2545–2554.
https://doi.org/10.1158/1078-0432.CCR-15-1927
Published: 12 May 2016
View article titled, Silencing of <em>CD24</em> Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Open the PDF for Silencing of <em>CD24</em> Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (4): 1018–1027.
https://doi.org/10.1158/1078-0432.CCR-15-1110
Published: 14 February 2016
View article titled, Analysis of <em>mTOR</em> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Open the PDF for Analysis of <em>mTOR</em> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors in another window
Includes: Supplementary data
Journal Articles

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6935–6942.
https://doi.org/10.1158/1078-0432.CCR-13-1266
Published: 16 December 2013
View article titled, Large-scale Analysis of <em>PDGFRA</em> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Open the PDF for Large-scale Analysis of <em>PDGFRA</em> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib in another window
Includes: Supplementary data
Journal Articles

Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-0739
Published: 13 August 2013
View article titled, Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Open the PDF for Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma in another window
Includes: Supplementary data
Journal Articles

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Yan Kong, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lu, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1684–1691.
https://doi.org/10.1158/1078-0432.CCR-10-2346
Published: 31 March 2011
View article titled, Large-Scale Analysis of <em>KIT</em> Aberrations in Chinese Patients with Melanoma
Open the PDF for Large-Scale Analysis of <em>KIT</em> Aberrations in Chinese Patients with Melanoma in another window
Includes: Supplementary data
Journal Articles

Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit

Jun Guo, Udit N. Verma, Richard B. Gaynor, Eugene P. Frenkel, Carlos R. Becerra
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3333–3341.
https://doi.org/10.1158/1078-0432.CCR-03-0366
Published: 24 May 2004
View article titled, Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit
Open the PDF for Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit in another window